Webcast Alert: Aastrom to Host First Quarter Investor Conference Call
02 November 2010 - 5:00AM
Aastrom Biosciences, Inc. (Nasdaq:ASTM) announces the following
webcast:
What: |
Aastrom Biosciences, Inc., First
Quarter Fiscal Year 2011 Investor Conference Call |
|
|
|
|
|
|
|
|
|
|
When: |
Monday, November 8, 2010 @ 9:30
am (ET) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Where: |
http://www.aastrom.com/investor.cfm |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
How: |
-- The conference call will be
available live in the Investors section of Aastrom's website at
http://www.aastrom.com/investor.cfm. Please access the site at
least 15 minutes prior to the scheduled start time in order to
download the required audio software if necessary (RealPlayer or
Windows Media Player). |
|
-- To participate in the live call by
telephone, please call (877) 312-5881 and reference Aastrom's first
quarter conference call. If calling from outside the U.S.,
please use the international phone number (253) 237-1173. |
|
|
|
|
|
|
|
|
|
-- A podcast will also be
available after the live event at
http://www.aastrom.com/events.cfm. |
If you are unable to participate during the live call, the
webcast will be available for replay at
http://www.aastrom.com/events.cfm until February 8, 2011. A replay
of the call will also be available until 12:00 am (ET) on Monday,
November 15, 2010, by calling (800) 642-1687, or from outside the
U.S. at (706) 645-9291. The passcode for the replay is
17933343.
About Aastrom Biosciences
Aastrom Biosciences is an emerging biotechnology company
developing expanded autologous cellular therapies for use in the
treatment of severe cardiovascular diseases. The company's
proprietary cell-processing technology enables the production of
cellular therapies expanded from a patient's own bone marrow and
delivered directly to damaged tissues. Aastrom has advanced its
cell therapies into late-stage clinical development, including a
planned Phase 3 clinical program for the treatment of patients with
critical limb ischemia and two ongoing Phase 2 clinical trials in
patients with dilated cardiomyopathy. For more information, please
visit Aastrom's website at www.aastrom.com.
The Aastrom Biosciences, Inc. logo is available at
http://www.globenewswire.com/newsroom/prs/?pkgid=3663
CONTACT: Berry & Company
Media Contact
Stephen Zoegall
212 253-8881
szoegall@berrypr.com
Aastrom Biosciences
Investor Contact
Kimberli O'Meara
734 930-5777
ir@aastrom.com
Vericel (NASDAQ:VCEL)
Historical Stock Chart
From Jun 2024 to Jul 2024
Vericel (NASDAQ:VCEL)
Historical Stock Chart
From Jul 2023 to Jul 2024